As restoration and reactivation of STING pathway in tumor cells can reinstate their antigenicity as well as T cell tumor trafficking, a key question for future work will be if this strategy could improve the efficacy of T cell-based immunotherapies in patients with melanoma particularly those involving adoptive cell transfer of autologous TIL. This evidence concerns the gene STING1 and neoplasm.